SAB Biotherapeutics, Inc.
SABSW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $10.5K in total; no superinvestor holds it.
Other share classesSABS
Q4 2021 vs. Q3 2021
How the institutions holding SAB Biotherapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 0 | 22 | +22 |
| Shares | 0 | 1.82M | +1.82M |
| Value | $0 | $3.10M | +$3.10M |
New holders (22)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Shaolin Capital Management LLC | 841,795 | $1.51M | 0.04% |
| Balyasny Asset Management LLC | 281,107 | $503.0K | 0.00% |
| Yakira Capital Management, Inc. | 115,785 | $207.0K | 0.03% |
| CVI Holdings, LLC | 58,320 | $104.0K | 0.01% |
| Integrity Capital Management (HK) Ltd | 54,433 | $97.0K | 0.31% |
| Maven Securities LTD | 50,000 | $90.0K | 0.01% |
| Rivernorth Capital Management, LLC | 46,665 | $84.0K | 0.00% |
| Equitec Proprietary Markets, LLC | 45,000 | $81.0K | 0.04% |
| HRT Financial LP | 44,982 | $80.0K | 0.00% |
| Fort Baker Capital Management LP | 36,693 | $66.0K | 0.01% |
| Morgan Stanley | 31,407 | $56.0K | 0.00% |
| Walleye Capital LLC | 23,258 | $42.0K | 0.00% |
| Context Capital Management, LLC | 24,203 | $38.0K | 0.00% |
| Citadel Advisors LLC | 19,628 | $35.0K | 0.00% |
| Bluefin Capital Management, LLC | 19,249 | $34.0K | 0.00% |
| Walleye Trading LLC | 15,505 | $28.0K | 0.00% |
| Jane Street Group, LLC | 13,550 | $24.0K | 0.00% |
| JPMorgan Chase & Co | – | $21.0K | 0.00% |
| UBS Group AG | 2,888 | $5.00K | 0.00% |
| Tower Research Capital LLC (TRC) | 48 | $0 | 0.00% |
| Radcliffe Capital Management, L.P. | 80,897 | – | – |
| LMR Partners LLP | 16,300 | – | – |
Sold out (0)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
None.